Literature DB >> 1120964

The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs.

P E Setler, R G Pendleton, E Finlay.   

Abstract

The cardiovascular effects of dopamine (DA) were studied in anesthetized dogs with special attention to the susceptibility of these effects to inhibition by catecholaminergic receptor blocking drugs. Dopamine given by rapid i.v. injection at 1 and 3 mug/kg produced depressor responses whereas doses from 9 to 81 mug/kg produced pressor resposes and increases in cardiac contractile force. Propranolol inhibited the increases in cardiac contractility whereas phenoxybenzamine potentiated the depressor effect of low doses of DA and reversed the pressor effect of high doses. Bulbocapnine blocked the depressor effect of DA in both phenoxybenzamine and propranolol-treated dogs. Pimozide, however, had no effect on the depressor response to DA. In hemodynamic studies, DA reduced blood pressure, total peripheral resistance and renal vascular resistance. Cardiac output and renal blood flow were increased. Bulbocapnine, but not pimozide, abolished the effects of DA on blood pressure, vascular resistance and renal blood flow. In conscious dogs, pimozide abolished apomorphine-induced emesis (an effect mediated by DA receptors in the central nervous system) whereas bulbocapnine had no effect. Therefore, the peripheral vascular and central dopamine receptors may be pharmacologically distinct.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1120964

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Effect of bulbocapnine as a peripheral dopamine receptor antagonists in the anesthetized cat.

Authors:  R G Pendleton; E Finlay; S Sherman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

Authors:  W D Kerns; E Arena; D G Morgan
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  Demonstration of vascular dopamine receptors in membranes from rabbit renal artery using 3H-spiroperidol binding.

Authors:  O E Brodde
Journal:  Experientia       Date:  1981-10-15

4.  Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Authors:  G Bise; C Foletti; C Beretta-Piccoli; P Weidmann; W H Ziegler; R Mordasini; C Bachmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Lack of pressor effect of dopamine in the pentobarbital-anesthetized rat.

Authors:  L F Obika
Journal:  Experientia       Date:  1987-08-15

6.  Antagonism of the renal vasodilator activity of dopamine by metoclopramide.

Authors:  R A Hahn; J R Wardell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-11       Impact factor: 3.000

7.  In vitro steroidogenic properties of FK 33 824, a stable analog of methionine-enkephalin. Opiate-dopamine interaction in the control of aldosterone production.

Authors:  M Bevilacqua; T Vago; U Raggi; D Scorza; M Proverbio; E Malacco; G Norbiato
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

8.  The role of presynaptic receptors in the cardiovascular actions of N,N-di-n-propyldopamine in the cat and dog.

Authors:  R Massingham; M L Dubocovich; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-10       Impact factor: 3.000

9.  Haemodynamic effects of dopamine, epinephrine and orciprenaline (Alupent) in patients early after cardiac surgery.

Authors:  R Gattiker; E Schmid
Journal:  Intensive Care Med       Date:  1978-01       Impact factor: 17.440

10.  Dopamine in the conscious dog with chronic heart-block. Mechanisms of chronotropic cardiac effects.

Authors:  M Boucher; C Dubray; P Duchêne-Marullaz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.